Publications 2022

Carm KT, Johannessen B, Bogaard M, Bakken AC, Maltau AV, Hoff AM, Axcrona U, Axcrona K, Lothe RA, Skotheim RI (2022)
Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer
Int J Cancer, 152 (5), 945-951
DOI 10.1002/ijc.34226, PubMed 35880692

Kidd SG, Bogaard M, Carm KT, Bakken AC, Maltau AMV, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI (2022)
In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis
Mol Oncol, 16 (15), 2810-2822
DOI 10.1002/1878-0261.13225, PubMed 35574900

Publications 2021

Kidd SG, Carm KT, Bogaard M, Olsen LG, Bakken AC, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI (2021)
High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity
Neoplasia, 23 (6), 634-641
DOI 10.1016/j.neo.2021.05.012, PubMed 34107378

Publications 2019

Carm KT, Hoff AM, Bakken AC, Axcrona U, Axcrona K, Lothe RA, Skotheim RI, Løvf M (2019)
Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer
Sci Rep, 9 (1), 13579
DOI 10.1038/s41598-019-49964-7, PubMed 31537872

Publications 2018

Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI (2018)
Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity
Eur Urol, 75 (3), 498-505
DOI 10.1016/j.eururo.2018.08.009, PubMed 30181068

Publications 2017

Zhao S, Løvf M, Carm KT, Bakken AC, Hoff AM, Skotheim RI (2017)
Novel transcription-induced fusion RNAs in prostate cancer
Oncotarget, 8 (30), 49133-49143
DOI 10.18632/oncotarget.17099, PubMed 28467780

Publications 2014

Nome T, Hoff AM, Bakken AC, Rognum TO, Nesbakken A, Skotheim RI (2014)
High frequency of fusion transcripts involving TCF7L2 in colorectal cancer: novel fusion partner and splice variants
PLoS One, 9 (3), e91264
DOI 10.1371/journal.pone.0091264, PubMed 24608966

Publications 2013

Alagaratnam S, Harrison N, Bakken AC, Hoff AM, Jones M, Sveen A, Moore HD, Andrews PW, Lothe RA, Skotheim RI (2013)
Transforming pluripotency: an exon-level study of malignancy-specific transcripts in human embryonal carcinoma and embryonic stem cells
Stem Cells Dev, 22 (7), 1136-46
DOI 10.1089/scd.2012.0369, PubMed 23137282

Barros-Silva JD, Paulo P, Bakken AC, Cerveira N, Løvf M, Henrique R, Jerónimo C, Lothe RA, Skotheim RI, Teixeira MR (2013)
Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer
Neoplasia, 15 (7), 720-6
DOI 10.1593/neo.13232, PubMed 23814484

Publications 2012

Sveen A, Bakken AC, Ågesen TH, Lind GE, Nesbakken A, Nordgård O, Brackmann S, Rognum TO, Lothe RA, Skotheim RI (2012)
The exon-level biomarker SLC39A14 has organ-confined cancer-specificity in colorectal cancer
Int J Cancer, 131 (6), 1479-85
DOI 10.1002/ijc.27399, PubMed 22173985

Publications 2011

Løvf M, Thomassen GO, Bakken AC, Celestino R, Fioretos T, Lind GE, Lothe RA, Skotheim RI (2011)
Fusion gene microarray reveals cancer type-specificity among fusion genes
Genes Chromosomes Cancer, 50 (5), 348-57
DOI 10.1002/gcc.20860, PubMed 21305644

Sagona AP, Nezis IP, Bache KG, Haglund K, Bakken AC, Skotheim RI, Stenmark H (2011)
A tumor-associated mutation of FYVE-CENT prevents its interaction with Beclin 1 and interferes with cytokinesis
PLoS One, 6 (3), e17086
DOI 10.1371/journal.pone.0017086, PubMed 21455500

Publications 2009

Bakken AC (2009)
Exon-specific biomarkers in cancer: experimental validation of exon microarray data from colorectal and testicular cancers
A.C. Bakken, Oslo, 83 s.
BIBSYS 094129622